الفهرس 
List of ContentsOnly 14 pages are availabe for public view
 |  | from | 165 |  |  |
| | | from | 165 | | |
Abstract
Hepatitis C is a major cause of chronic liver disease worldwide and Egypt had high burden of liver disease from viral hepatitis.The discovery of direct-acting antiviral agents (DAAs) has dramatically changed HCV treatment by increasing the cure rate and decreasing the duration of therapy. Psychiatric and psychosocial contraindications to treatment are reduced due to shorter duration of therapy and improved side effect profiles.The sofosbuvir and daclatasvir combination is associated with a high rate of SVR in difficult-to-treat patients infected with genotype 1 Mental illness are significantly higher in chronic HCV patients than in the general population. HCV infection lead to psychiatric symptoms by inflammatory routes, direct brain neurotoxicity, metabolic and neurotransmitter pathway derangement and immune-mediated responses. Currently, the extent of psychiatric effects attributed to DAA agents is unclear. There is a paucity of data specifically addressing neuropsychiatric complications of these drugs.This is a prospective cohort study, aimed to evaluate the psychiatric manifestations, specifically depression and anxiety in patients with chronic hepatitis C infection who received sofosbuvir based DAAs. Also, to evaluate effect of gender difference on psychiatric manifestation, In addition, we aimed to identify possible risk factor for psychiatric manifestation of sofosbuvir based DAAs.170 participants recruited from Outpatients Clinics, Virology Unit of Al-Rajhi Liver Hospital and Assiut liver center. Participants were interviewed throughout the period from December 2019 to December 2020.In this study, we categorized participants into 2 groups regarding gender, 97 males and 73females were included.They received treatment according to the protocol provided by the National Committee for control of viral hepatitis in Egypt (NCCHC) guidelines for the management of adult patients with HCV infection recommended given DAAs therapy in the form of once daily oral dose of sofosbuvir 400 mg and daclatasvir 60 mg according to body weight in chronic hepatitis C (non-cirrhotic)ll participants were evaluated at the start of the study and then during the treatment course at 1st, 2nd, 3rd months and then three months after the end of therapy.In this study, There was a significant difference regarding body mass index (BMI), Occupation, and Hypertension between males and females of the studied group. Body mass index (BMI) had a higher mean in females (26.50 ± 4.28) than males (24.69 ± 3.74).Females had a higher percentage of non-workers while all males worked (manual and official workers). Regarding the male group, manual workers had a higher percentage than office workers.The percentage of Hypertension disease was significantly higher in males (8.2%) than females (1.4%).mong studied groups, There was no statistically significant difference among the studied groups in mean values of subscales and total of SIFFM.A higher percentage of moderate class was observed in neuroticism, extraversion, and agreeableness compared to low class. In contrast, the low class was higher in the percentage regarding openness to experience and conscientiousness than the moderate class.Regarding gender, the moderate class was higher in males than females regarding all subscales of SFFM except conscientiousness. There was no significant difference in laboratory data among the studied groups. However, it was notice that females had higher mean of HCV RNA and liver function test in compared to males. 97.9% of males achieved SVR, while 93.2% females achieved SVR without significant statistical difference between them.